Biotinylated Human PRLR Protein
Catalog No: PRLR-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human PRLR Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Gln25-Asp234 (UniProt accession: P16471-1).
Product Details
- Molecular Aliases
- PRL-R; HPRL; MFAB; Prolactin R
- Protein Length
- Gln25-Asp234
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 27.32 kDa. Due to glycosylation, the protein migrates to 32-40 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in 50mM Tris, 150mM NaCl (pH 7.5). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human PRLR on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human PRLR is greater than 95% as determined by SEC-HPLC.
Immobilized Biotinylated Human PRLR, His Avi tag at 0.5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-PRLR Antibody, hFc Tag with the EC50 of 7.2ng/ml determined by ELISA. (QC Test)
Background
Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop new therapies against PRLR target. Bispecific antibodies (BsAbs) could guide immune cells toward tumor cells, and produced remarkable effects in some cancers.
References
- Zhou Y, Zong H, Han L, Xie Y, Jiang H, Gilly J, Zhang B, Lu H, Chen J, Sun R, Pan Z, Zhu J. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer. J Exp Clin Cancer Res. 2020 May 12;39(1):87. doi: 10.1186/s13046-020-01564-4. PMID: 32398042; PMCID: PMC7216678.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.